Cough-Focused Trevi Therapeutics Stock Skyrockets on Positive Trial News

Trevi Therapeutics (NASDAQ: TRVI) stock surged over 80% on Thursday, driven by positive results from a sample size re-estimation (SSRE) for its Phase 2b CORAL trial. The SSRE confirmed no changes were needed to the current sample size of 160 patients, indicating the trial's progress and potential success. This news, coupled with the trial's 75% enrollment and expected topline results in H1 2025, has boosted investor confidence in the company's potential to revolutionize chronic cough treatment.

Trevi's investigational therapy, Haduvio™, is an oral extended-release formulation of nalbuphine, targeting chronic cough in idiopathic pulmonary fibrosis (IPF) patients. Unlike existing treatments, Haduvio™ works by rebalancing receptors in both the central and peripheral nervous systems, offering a novel approach to treating chronic cough. This unique mechanism of action has shown promising results, with Haduvio™ reducing daytime cough frequency by 75% in IPF subjects in its Phase 2 CANAL trial.

The positive outcome from the sample size re-estimation for the CORAL trial further boosts investor confidence in Trevi Therapeutics' potential to address chronic cough conditions. With no approved therapies in the U.S. or U.K., Trevi's Haduvio™ could fill a significant gap, potentially reaching millions of patients. Moreover, Trevi's expansion into refractory chronic cough (RCC) further broadens its market potential.

Chronic cough affects up to 10% of adults, with significant impacts on quality of life. Trevi's focus on this condition presents a substantial market opportunity, as the company advances its clinical development and investors continue to benefit from its promising pipeline and unmet market needs.




In conclusion, Trevi Therapeutics' stock surge on Thursday reflects investors' optimism about the company's potential to revolutionize chronic cough treatment. With positive trial results and a unique mechanism of action, Trevi's Haduvio™ could fill a significant gap in the market and address the unmet needs of millions of patients. As Trevi continues to advance its clinical development, investors may continue to benefit from its promising pipeline and market opportunities.